225Ac-PSMA derivatives achieve semi-automatic, electroless synthesis at 20°C, ready for clinical application.
Electroless semi-automatic synthesis of 225Ac-labeled PSMA-derivatives for clinical application and evaluation of rechelation capability.
Background
Prostate cancer theranostics increasingly utilize alpha-emitting radionuclides like Actinium-225 (225Ac) for targeted therapy, often paired with PSMA (Prostate-Specific Membrane Antigen) ligands. Current radiolabeling methods can be complex, requiring heating or environmentally persistent chemicals like trifluoroacetic acid (TFA), which hinder "green" radiochemistry and kit development. The goal is to simplify this process, enabling quantitative radionuclide chelation at ambient temperatures (around 20°C) for sterile, ready-to-use kits, similar to established [68Ga]Ga-PSMA-11 kits. This paper addresses the need for robust, semi-automatic, and eco-friendly 225Ac labeling.